Skip to content

Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.

Robert B. Kargbo

ACS Medicinal Chemistry Letters June 12, 2025 DOI: 10.1021/acsmedchemlett.5c00265 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Interventions DMT 5-MeO-DMT
Topics 5-MeO-DMT Depression DMT Psychedelic-assisted therapy
Keywords Entheogenic treatment Hallucinogen-assisted therapy Novel drug delivery Injectable drugs Nasal sprays Drug administration Mental health therapy Antidepressant therapy Quick-onset medications Short-duration effects Acute interventions
Citations 1
Key findings Parenteral and intranasal formulations of DMT and 5-MeO-DMT overcome bioavailability and metabolism limitations, enabling rapid-onset, short-duration therapeutic effects for conditions like treatment-resistant depression.

Abstract

Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric conditions such as treatment-resistant depression while optimizing tolerability, scalability, and clinical utility.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • State of the evidence: DMT for depression Supports

    Argues that parenteral and intranasal DMT and 5-MeO-DMT formulations overcome bioavailability and metabolism limits, enabling rapid-onset, short-duration therapeutic effects for treatment-resistant depression.

    Synthesized

Comparable studies

Other narrative reviews on DMT for depression, most cited first.

Study Year Design Participants
Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Registered clinical trials on clinicaltrials.gov evaluating psychedelics for... 2021 Review n = 70
Role of Psychedelics in Treatment-Resistant Depression. 2023 Review
Psilocybin and Other Classic Psychedelics in Depression. 2024 Review
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression 2025 Review
Ayahuasca for the Treatment of Depression. 2022 Review

Citations in the library

Cited by 1

Cites 4

Related reading

Explore topics

5-MeO-DMT Depression DMT Psychedelic-assisted therapy

By condition and practice

DMT for depression